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A Case of Resistance to Thyroid Hormone with Thyroid Cancer 
Resistance to thyroid hormone (RTH) is an autosomal dominant hereditary disorder that is 
difficult to diagnose because of its rarity and variable clinical features. The magnitude of 
RTH is caused by mutations in the thyroid hormone receptor beta (TRβ) gene. We recently 
treated a 38-yr-old woman with RTH who had incidental papillary thyroid carcinoma. She 
presented with goiter and displayed elevated thyroid hormone levels with an unsuppressed 
TSH. She was determined to harbor a missense mutation of M310T in exon 9 of the TRβ 
gene, and diagnosed with generalized RTH. This mutation has not yet been reported in 
Korea. RTH is very rare and easily overlooked, but should be considered in patients who 
present with goiter and elevated thyroid hormone levels with an unsuppressed TSH. The 
association between thyroid cancer and RTH needs further study.
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CASE REPORT
Oncology & Hematology
INTRODUCTION
Resistance to thyroid hormone (RTH) is a rare an autosomal 
dominant hereditary disorder (1). In the majority of cases, RTH 
is caused by mutations in the thyroid hormone receptor beta 
(TRβ) gene. The clinical presentation is variable, but common 
features include goiter, an absence of the classic thyrotoxic symp-
toms and metabolic consequences of elevated thyroid hormone 
levels, and a normal or exaggerated thyroid stimulating hormone 
(TSH) response to thyrotropin-releasing hormone (TRH). Until 
now over 1,000 cases have been identified around the world, 
and nine cases have been reported in Korea (2-9).
  We recently encountered a case of RTH with incidental mi-
cropapillary thyroid carcinoma. The association between RTH 
and thyroid cancer has not yet been clarified, but there is evi-
dence to suggest that RTH may play a contributory role.
  Here, we present a case of RTH with thyroid cancer along with 
the mutation analysis for the TRβ gene.
 
CASE REPORT
A 38-yr-old Korean woman visited a private clinic for the evalu-
ation of anterior neck swelling. The initial laboratory examina-
tion revealed an elevated levels of serum thyroid hormone with-
out accompanying TSH suppression (free T4 2.67 ng/dL [range, 
0.64-1.72] and TSH 1.82 μIU/mL [range, 0.4-4.5]). She had no 
signs or symptoms of typical thyrotoxicosis except diffuse goiter 
and mild palpitations. However, due to findings of elevated se-
rum thyroid hormone levels and goiter, she was diagnosed with 
Graves’ disease, and prophylthiouracil (PTU) was prescribed. 
After three months of PTU (100 mg three times daily), she com-
plained of generalized weakness, a weight gain of about 3 kg, 
and generalized edema. Consequently, she was referred to our 
hospital.
  When first seen at our hospital on December 9, 2008, her height 
and weight were 162 cm and 49 kg, respectively, with a blood 
pressure of 97/68 mmHg and a pulse rate of 96 beats/min. Her 
thyroid gland was symmetrically enlarged, and exophthalmos 
and myxedematous skin lesions were absent. Past medical his-
tory was significant for goiter first detected at age 13. At that time, 
the physician recommended regular checks for thyroid func-
tion because of elevated levels of thyroid hormones, but she was 
lost to follow-up. Her family history included one sister who had 
a diffuse goiter and a thyroid nodule.
  The laboratory examination revealed an elevated level of TSH 
despite an elevated levels of thyroid hormone [total T3 181 ng/dL 
(range, 76-190), free T4 2.50 ng/dL and TSH 10.23 μIU/mL]. Thy-
roid autoantibodies against thyroperoxidase, thyroglobulin, and 
TSH-receptor were all negative. Thyroid ultrasonography (USG) 
revealed several micro-nodules in both lobes. USG-guided fine-
needle aspiration was performed for the nodule which showed 
suspicious features of malignancy in the right thyroid lobe (Fig. Kim HK, et al.  •  Resistance to Thyroid Hormone with Thyroid Cancer
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1), and the cytologic diagnosis was papillary thyroid carcinoma. 
A 99m technetium thyroid scan showed diffuse enlargement of 
the thyroid gland with increased uptake (10.1%) (Fig. 2). PTU 
was discontinued due to TSH elevation and the occurrence of 
hypothyroid symptoms. After PTU was stopped for one month, 
hypothyroid symptoms disappeared and thyroid function tests 
(TFTs) revealed elevated thyroid hormone levels [free T4 2.20 
ng/dL and total T3 141 ng/dL] and a nearly normal level of TSH 
(5.60 μIU/mL).
  The differential diagnosis at this point was between RTH and 
a TSH-secreting pituitary adenoma based on the TFTs findings. 
TSH-secreting pituitary adenoma was ruled out because the 
patient had no clinical features of thyrotoxicosis, a negative MRI 
of the pituitary gland, a normal level of the α-subunit of TSH (0.36 
mIU/mL, range, 0-0.9), and an exaggerated response of TSH to 
a thyrotropin-releasing hormone (TRH) stimulation test (Fig. 3). 
  Accordingly, genomic DNA was isolated from the peripheral 
blood leukocytes of the patient with a G-DEX
TM Ilb Genomic 
DNA Extraction Kit (Intron Biotechnology, Seongnam, Korea). 
PCR amplification was conducted on seven coding exons (from 
exon 4 to 10) of the TRβ gene. The sequences were analyzed us-
ing the computational software ABI 3730 XL (Applied Biosys-
tems, Foster City, USA). A point mutation was detected in exon 9 
of the TRβ gene that caused the substitution of threonine (ACG) 
for methionine (ATG) at codon 310 (M310T). This mutation has 
not yet been reported in Korea. The patient’s sister had normal 
TFTs and no mutation by DNA sequencing analysis (Fig. 4).
  Ultimately, the patient was diagnosed with RTH and papil-
lary thyroid carcinoma. She underwent a total thyroidectomy 
and the pathologic diagnosis was two micropapillary thyroid 
carcinomas in both lobes (0.4 cm in the right and 0.2 cm in the 
left lobe). After surgery, she received levothyroxine (L-T4) at 150 
μg/day). After three months of L-T4 therapy, her TSH level was 
still elevated (TSH 45.1 μIU/mL) and she complained about 
symptoms of hypothyroidism; therefore, we increased the dose 
of L-T4 to 200 μg/day. After two months, her TSH level decreased 
to 15.5 μIU/mL, and most of her hypothyroid symptoms disap-
peared. Ultimately the dose of L-T4 was increased to 250 μg/day 
titrated to achived a TSH level comparable to the preoperative 
value.
 
DISCUSSION
Inappropriate secretion of TSH and the co-existence of elevated 
thyroid hormone has been noted in several circumstances, in-
cluding intermittent administration with L-T4, TSH-secreting 
pituitary adenoma, and RTH (10). RTH is distinguished from 
TSH-secreting pituitary adenoma by an exaggerated response 
to TRH, normal levels of the TSH α subunit, and a normal pitu-
itary gland on sella-MRI. RTH is characterized by reduced clini-
cal and biochemical manifestations of thyroid hormone action 
relative to the elevated circulating thyroid hormone levels. The 
Fig. 1. The ultrasonography of thyroid showed 0.6 cm hypoechoic nodule in the right 
lobe with taller-than-wide appearance, which was suspicious for malignancy.
Fig. 2. The 
99mTechnetium thyroid scan showed diffuse enlargement of both lobes of 
the thyroid with homogenously increased uptake (10.1%).
5 cm
Fig. 3. Exaggerated response of TSH to TRH stimulation was observed in the patient 
with resistance to thyroid hormone.
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linkage between RTH and the TRβ gene was detected in 1988 
(11). About 90% of RTH patients carry mutations in the T3-bind-
ing domain between exon 4 and exon 10 of the TRβ gene. The 
majority of previously described mutations were missense mu-
tations that induced single amino acid substitutions.
  Most patients of RTH are clinically euthyroid, some individu-
als may appear to be hypothyroid or hyperthyroid. Furthermore, 
the same subject can manifest signs and symptoms of hypothy-
roidism in one tissue, while the findings may be suggestive of 
thyrotoxicosis in other tissues (1). On the basis of clinical fea-
tures, three different forms of RTH have been described: gener-
alized RTH (GRTH), pituitary RTH (PRTH), and peripheral tis-
sue RTH (PTRTH). GRTH patients, the most common form, 
appear eumetabolic despite elevated level of thyroid hormones 
maintained by the hypersecretion of TSH in response to hypo-
thalamic TRH. PRTH patients generally display thyrotoxic. Ad-
ministration of an anti-thyroid drugs may improve the symp-
toms. PTRTH patients manifest symptoms and signs of hypo-
thyroidism, despite of normal serum thyroid hormone and TSH 
levels (12).
  Treatment of RTH should be aimed at maintaining a normal 
metabolic status. In our case, administration of anti-thyroid 
drugs under the misdiagnosis of Graves’ disease resulted in an 
increase in serum TSH and the appearance of symptoms of hy-
pothyroidism, while thyroid hormone levels remained elevated. 
As expected, large amounts of L-T4 were needed in our patient 
after total thyroidectomy. Titration should be achieved by as-
sessing tissue responses. Restoration of the preoperative levels 
of TSH is the recommended target in GRTH. 
  The RTH in our patient was accompanied by two small papil-
lary thyroid cancers. The precise contribution of RTH to thyroid 
tumorigenesis is not fully understood, but there is evidence to 
suggest that they may play contributory roles. About 95% of RTH 
patients have diffuse goiter, and continuous stimulation of the 
thyroid by excess TSH may be related to the formation of thyroid 
nodules and the growth of thyroid cancer (13). Previous patho-
logical examinations of the thyroid in RTH cases have revealed 
hyperplasia of the follicular epithelium, sometimes accompa-
nied by papillary proliferation probably due to continuous stim-
ulation by TSH (12). Not only the effect of thyroid, but the cases 
of co-existence of pituitary tumor were reported (14). TRβ mu-
tants may also have oncogenic actions. Abnormal expression 
and somatic mutation at various sites of the TRβ gene have been 
described in human cancers of the liver, kidney, breast and colon 
(15-19). Puzianowska-Kuznicka et al. (16) conducted the se-
quencing of TRβ1 and TRα1 cDNAs. TRβ1 and TRα1 mutations 
were found in 93.8% and 62.5% of papillary cancer cases, respec-
tively. But no mutations were found in healthy thyroid controls, 
and only 11.1% and 22.2% of thyroid adenomas had such TRβ1 
or TRα1 mutations. Suzuki et al. (20) generated a mouse model 
(TRβ
PV/PV mice) of thyroid cancer that harbored a C-terminal 14 
amino acid frame-shift mutation in the TRβ gene.
  Despite accumulating evidence for a possible role for TR mu-
tants in thyroid tumorigenesis, an elevated rate of thyroid can-
cers in RTH patients has not yet been observed. It may be that 
most cases of RTH in humans have heterozygous mutations of 
TRβ, unlike the TRβ
PV/PV homozygous mouse model. Other ge-
netic alterations such as BRAF mutation, which is commonly 
detected the Korean patients with PTC, may also be required to 
initiate thyroid cancer. Unfortunately, analyses of BRAF
V600E mu-
tation or activities of PI3K could not be conducted in our case.
  In conclusion, RTH is very rare and easily overlooked, but must 
be considered in patients who present with goiter and elevated 
thyroid hormone levels with unsuppressed TSH. Further stud-
ies to address the association between thyroid cancer and RTH 
will shed insight on the molecular and cellular mechanisms of 
thyroid tumorigenesis.
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TRβ gene showed a substitution of threo-
nine (ACG) for methionine (ATG) at codon 
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